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Abstract: The gut microbiota is a remarkable asset for human health. As a key element 
in the development and prevention of specific diseases, its study has yielded a new field of 
promising biotherapeutics. This review provides comprehensive and updated knowledge 
of the human gut microbiota, its implications in health and disease, and the potentials and 
limitations of its modification by currently available biotherapeutics to treat, prevent and/
or restore human health, and future directions. Homeostasis of the gut microbiota main-
tains various functions which are vital to the maintenance of human health. Disruption of 
the intestinal ecosystem equilibrium (gut dysbiosis) is associated with a plethora of human 
diseases, including autoimmune and allergic diseases, colorectal cancer, metabolic diseases, 
and bacterial infections. Relevant underlying mechanisms by which specific intestinal bac-
teria populations might trigger the development of disease in susceptible hosts are being 
explored across the globe. Beneficial modulation of the gut microbiota using biotherapeutics, 
such as prebiotics, probiotics, and antibiotics, may favor health-promoting populations of 
bacteria and can be exploited in development of biotherapeutics. Other technologies, such 
as development of human gut models, bacterial screening, and delivery formulations eg, 
microencapsulated probiotics, may contribute significantly in the near future. Therefore, 
the human gut microbiota is a legitimate therapeutic target to treat and/or prevent various 
diseases. Development of a clear understanding of the technologies needed to exploit the 
gut microbiota is urgently required.
Keywords: gut microbiota, human health, dysbiosis, biotherapeutics, probiotics, 
microencapsulation
Introduction
The human gastrointestinal tract houses a huge microbial ecosystem, the gut   microbiota. 
This intestinal ecosystem is partially responsible for maintaining human health. 
However, particular changes in the ecosystem might contribute to the development 
of certain diseases. With this in mind, there is a need for an exhaustive review on the 
functions of the gut microbiota, occurrence of gut dysbiosis (alteration of the micro-
biota), mechanisms by which intestinal bacteria can trigger development of disease, 
how this ecosystem can be exploited for understanding human health, development 
of biotherapeutics, expert opinion on current biotherapeutics, and future perspectives. 
This review presents a descriptive and comprehensive analysis on “the good, the bad, 
and the ugly” of the gut microbiota, and methods to study these and their modulation 
of human health.Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Composition
The human gut microbiota represents the trillions of 
microorganisms located in our intestines. Collectively, the 
number of intestinal microbial cells is 10 times greater 
than the number of human body cells.1 It was recently 
demonstrated that the microbiome, which represents the 
collective genomes of the gut microbiota, is approxi-
mately 150 times larger than the human gene complement, 
with an estimated set of 3.3 million microbial genes.2 
Seven bacterial divisions constitute the gut microbiota,   
ie, Firmicutes, Bacteroides, Proteobacteria, Fusobacteria, 
Verrucomicrobia, Cyanobacteria, and Actinobacteria, 
with Firmicutes and Bacteroides being the most abundant 
species.3 Bacterial communities exhibit quantitative and 
qualitative variations along the length of the gastrointes-
tinal tract due to host factors (eg, pH, transit time, bile 
acids, digestive enzymes, and mucus), nonhost factors 
(eg, nutrients, medication, and environmental factors), 
and bacterial factors (eg, adhesion capacity, enzymes, and 
metabolic capacity).4
Acquisition
It is generally accepted that humans are born with a sterile 
gut. However, new evidence suggests that colonization of the 
gastrointestinal tract starts before birth, with the fetus ingest-
ing amniotic fluid containing microbes.5 Subsequently, intes-
tinal colonization is acquired during the first months of life, 
with aerobic and facultative anaerobic   colonization, followed 
by obligate anaerobes and Bifidobacteria.6   Establishment of 
the gut microbiota is recognized as a complex process influ-
enced by factors at the level of the host and of the microbes 
themselves.3
exploration
Study of the composition of human colonic microbiota and 
metabolism has methodological and ethical limitations. 
Attempts to circumvent these limitations have led to the 
development of models. In vitro models are of interest for 
ecological, fermentation, and metabolic studies.7 These 
provide reproducible results and controlled mechanistic 
studies (Table 1). Fecal inocula are most often utilized as a 
representation of the intestinal microbiota.2 In vivo models 
for the exploration of the gut microbiota encompass various 
species of laboratory animals. Effects of the indigenous 
microbiota on the host have been determined by gnotobiol-
ogy, ie, selective colonization of germ-free animals with 
defined organisms.8
Analysis
Until recently, the analysis of bacterial ecosystems was 
performed by growth on defined media, which has some 
limitations because this method is labor-intensive and, more 
importantly, only 80% of stool bacteria can be cultivated.6,8 
As a consequence, new molecular techniques have been 
developed. In terms of qualitative measurements of the 
microbiota, techniques such as fingerprinting (denaturing 
gradient gel electrophoresis), terminal restriction fragment 
length polymorphism, ribosomal intergenic spacer analysis, 
and 16S ribosomal RNA sequencing are widely used.8–11 
Specifically, genome sequencing has provided tremendous 
information in the microbial world, spearheading technolo-
gies such as microarrays.8 New automated parallel sequenc-
ing technologies, based on the 16S ribosomal RNA gene 
present in all prokaryotes, can offer a cost-effective solution 
for rapid sequencing and identification of bacterial species 
of the gut. Prominent high-throughput sequencing tech-
nologies include 454 Life Sciences’ Genome SequencerTM, 
Applied Biosystems’ SOLiDTM 3 Plus system, Illumina’s 
Genome Analyzer IIx, and other technologies developed by 
Affymetrix, Helicos, Qiagen, and Microchip. For quantita-
tive measurements of the gut microbiota, fluorescence in situ 
hybridization, catalyzed reporter deposition-fluorescence in 
situ hybridization, quantitative polymerase chain reaction, 
and scanning electron microscopy in situ hybridization, can 
be useful.8,10–12 Fluorescence in situ hybridization allows for 
the visualization of microorganisms in their natural environ-
ment using labeled probes specific for selected bacteria. This 
method has been used for the determination of changes in 
the bacterial populations of fecal homogenates and in tissue 
sections from individuals with certain diseases. Catalyzed 
reporter deposition-fluorescence in situ hybridization is a 
modified method of fluorescence in situ hybridization which 
allows for in situ amplification using horseradish peroxidase, 
enhancing bacterial cell detection in samples where ribosomal 
RNA is insufficient for fluorescence in situ hybridization.12 
Real-time quantitative polymerase chain reaction is a recent 
and widely used technique for exploration of the roles of 
gut microflora in health and disease, based on the presence 
of specific RNA sequences. There is also scanning electron 
microscopic in situ hybridization which uses deposition of 
nanogold particles to enable detection12 (Table 2). Finally, 
metagenomics is an approach to analyze the genomic content 
of microbial communities living in a particular niche, such 
as the gut, and for identifying and quantifying the bacterial 
species present.8Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 1 in vitro and in vivo models of the human gut microbiota and their potentials and limitations
Models Description Main use Limitations References
In vitro
Static batch system Fresh feces or colonic contents  
suspended in buffer solution
Short-term metabolic and  
enzymatic studies
Rapid change in ecosystem  
composition
7
Semicontinuous batch  
system
Chemostat culture system of  
semicontinuous flow
Inoculated with defined bacteria, feces,  
or colonic content
Long-term studies on  
metabolic, ecologic, and  
dietary fermentation
Host factors are ignored
Stability of ecosystem is  
assumed
7
Continuous batch  
system
Chemostat culture system of  
continuous flow
Inoculated with defined bacteria, feces,  
or colonic content
Long-term studies on  
metabolic, ecologic, and  
dietary features of Gi  
microbiota
Host factors are ignored
Complex system to set up
Stability of ecosystem is  
assumed
7,105,106
In vivo
Laboratory animals Fresh feces or colonic contents from  
conventional microbiota animals
Metabolic, ecological, and  
preclinical studies
Differences between animals  
and humans gut microbiota  
composition
7,109,112
Gnobiotic animals Germ-free laboratory animals colonized  
with defined organisms or transferred  
microbiota from a laboratory animal or  
a human volunteer
Host-bacterial and bacterial- 
bacterial interaction studies
Alteration of bacterial  
interactions
7,10,49
Human volunteers Fresh feces or colonic contents from  
human volunteers
Metabolic, ecological,  
chemical, and clinical studies
ethical issues
Relevance of feces/colonic  
contents to represent the  
overall Gi microbiota
7,36,42
Abbreviation: Gi, gastrointestinal.
The good
The gut microbiota performs essential functions in mainte-
nance of health, including having protective, structural, and 
metabolic roles.
essential metabolic functions
Metabolic functions of the gut microbiota include production 
of vitamin, amino acid synthesis, and bile acid biotrans-
formation. Bile acid biotransformations, performed by 
microbial enzymes, have implications for cholesterol and 
glucose metabolism.13 Importantly, the microbiome provides 
biochemical pathways required for the fermentation of 
nondigestible substrates and endogenous mucus. Through 
fermentation, bacterial growth is stimulated, producing short-
chain fatty acids and gases.14 The major short-chain fatty 
acids produced are acetate, butyrate, and propionate. Other 
bacterial end products include lactate, ethanol, succinate, for-
mate, valerate, caproate, isobutyrate, 2-methyl-butyrate, and 
isovalerate. Bacterial fermentation is present in the cecum 
and colon, where the short-chain fatty acids are absorbed, 
stimulating the absorption of salts and water. One property 
of short-chain fatty acids is their trophic effect on the intes-
tinal epithelium.14 Butyrate is the preferred energy source for 
epithelial cells, and is almost entirely cleared by the colonic 
epithelium. Acetate is the principal short-chain fatty acid in 
the colon and the primary substrate for cholesterol synthesis. 
Finally, propionate supplementation in the diet was shown 
to reduce cholesterol levels in vivo.15,16 Clinical trials have 
yet to confirm these observations. Therefore, the metabolic 
activities performed by the gut microbiota are various and 
essential for host metabolism (Figure 1).
ensures protection
Pathogen displacement or “colonization resistance” is 
an accepted function of the gut microbiota. Commensal 
organisms prevent pathogenic colonization by competing 
for attachment sites and nutrients, and also through the pro-
duction and secretion of antimicrobials. Those mechanisms 
are relevant for reducing the level of lipopolysaccharides, 
peptidoglycans, bacterial CpG-DNA motifs, and superanti-
gens, which can all be detrimental to the host.17 The indig-
enous microbiota is also essential for development of the 
immune system.18 Germ-free mice display underdeveloped 
lymphatic systems, with fewer Peyer’s patches and isolated 
lymphoid follicles.19,20 Moreover, intestinal dendritic cells 
are fewer in germ-free animals, and there is evidence to 
support a role for bacterial signals in B cell development.21,22 
Furthermore, signals from intestinal bacteria appear impor-
tant for the development of regulatory T, T helper type 1 
and 2 cells, and T helper 17 cells.23–25 The first commensal Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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microorganism molecule shown to influence an immune 
response   beneficially was capsular polysaccharide A, pro-
duced by Bacteroides fragilis.26 Short-chain fatty acids, 
such as butyrate, may also exert potent immunomodulatory 
effects by suppressing nuclear factor-kB activation and/or 
by acting on G-coupled receptors, as demonstrated with 
acetate.27,28 These concepts illustrate a dynamic relation-
ship between the immune system and the microbiota. The 
intestinal mucosa averts threats by signaling to the innate 
immune system through pattern recognition receptors, 
such as toll-like receptors. Pattern recognition receptors 
recognize and bind to specific microbial macromolecules, 
referred to as microbial-associated molecular patterns. These 
include lipopolysaccharide, flagellin, peptidoglycan, and 
N-formylated peptides. In the intestinal mucosa, activation 
of pattern recognition receptors initiates nuclear factor-kB 
pathways, mitogen-activated protein kinase, and caspase-
dependent signaling cascades. These lead to the production 
and release of protective peptides, cytokines, chemokines, 
and phagocytes. The result can be a protective response to 
commensal bacteria, an inflammatory response to pathogenic 
organisms, or a trigger of apoptosis. Therefore, commensal 
bacteria of the gastrointestinal tract play active roles in the 
development and homeostasis of the immune system, as 
shown in Figure 1.
Structural and histological function
The microbiota ensures intestinal structure and function. 
Firstly, the mucus layer, which reflects the balance between 
mucus secretion and bacterial degradation, constitutes an 
obstacle to the uptake of antigens and proinflammatory 
molecules.29 There is evidence indicating that butyrate 
reinforces the colonic defense barrier by inducing the 
  secretion of mucins, trefoil factors, and antimicrobial 
peptides.30 Secondly, some bacterial communities may 
strengthen the barrier at the level of the tight junctions, 
Table 2 Available techniques for human gut microbiota characterization
Techniques Description Main use Limitations Reference
Culture-based Defined media used to isolate bacterial  
populations
Quantification/characterization  
of isolated colonies
Bacteria uncultivable
Species/strains level hardly  
detected
Labor-intensive
8,6
16S rRNA  
sequencing
Species/strains level sequencing Bacterial identification extensive data analysis 8,9–11
DGGe Denaturation of small PCR amplicons  
from extracted community DNA and  
gel migration
Comparative studies PCR amplicons too small to  
sequence information
8,11
Terminal RFLP Denaturation of full-length 16S rRNA  
PCR amplicons from extracted  
community DNA and gel migration
Communities comparison Limited taxonomic  
resolution
8,11
RiS analysis PCR amplification of IS region between  
16S-23S rRNA genes hybridized to  
fluorescently labeled primers
Characterization of complex  
bacterial communities
Complex bacterial  
identification
Lack of extensive database
8,11
FiSH Hybridization of fluorescently labeled  
oligonucleotide probes to 16S rRNA  
specific of targeted bacteria
Quantification of targeted  
bacterial groups/species
Novel species/strains  
unidentified
8,10,11
CARD-FiSH Modified FISH method: in situ  
amplification using horseradish  
peroxidase
Bacteria quantification if FISH  
inadequate
Novel species/strains  
unidentified
12
SeM in situ  
hybridization
Combination of in situ hybridization  
and SeM
Quantification of targeted  
bacterial groups/species
Novel species/strains  
unidentified
12
Quantitative PCR Specific bacterial groups/species  
targeted from a mix culture by  
quantitative PCR primers
Quantitative studies of  
complex system
Novel species/strains  
unidentified
Strain required for standard  
curve
8,10,11
DNA microarray Set of regular arranged spots of DNA  
recognition elements positioned on  
microscopic slides
Screening of human gut  
microbial communities
Low detection limit
Hybridization biases
Novel species/strains  
unidentified
8
Abbreviations: CARD, catalyzed reporter deposition; DGGE, denaturing gradient gel electrophoresis; FISH, fluorescence in situ hybridization; ISR, intergenic spacer; PCR, 
polymerase chain reaction; RFLP, restriction fragment length polymorphism; R, ribosomal; SeM, scanning electron microscopy.Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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ie, protein clusters that form a barrier between the lumen 
and the lamina propria. Moreover, the gut microbiota is 
involved in cell and tissue development. Butyrate regulates 
cell growth and differentiation, inhibiting transformed 
cell growth while encouraging reversion of cells from a 
neoplastic to a non-neoplastic phenotype.31 The cecum villi 
are longer and wider, while the colonic crypts are shorter 
and contain fewer cells in germ-free than conventionally 
reared animals, possibly due to an altered rate of epithelial 
cell turnover or to anatomical changes arising from a reduc-
tion in bacterial count.32 Moreover, indigenous microbes 
shape the development of the villus microvasculature, as 
demonstrated in germ-free animals colonized during or 
after completion of postnatal gut development.33 Therefore, 
most of the structural and morphological development of 
the gut contributes to and manages the gut bacterial system 
(Figure 1).
The bad
Dysbiosis is a state in which the microbiota becomes altered 
as a consequence of an alteration in the composition of 
the microbiota, a change in bacterial metabolic activity, 
and/or a shift in local distribution of communities. Many 
factors can alter the gastrointestinal ecosystem, including 
antibiotics, psychological and physical stresses, radiation, 
altered peristalsis, and dietary changes.34 At present, the 
focus is on the description of dysbiosis in a plethora of 
human disorders.
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Figure 1 Main beneficial functions of the human gut microbiota. Circles represent the three principal classes of functions performed by the bacteria that inhabit the gut. 
Arrows represent causal relationships.
Abbreviation: SCFA, short chain fatty acid.Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Autoimmune disease
Autoimmune diseases occur when the body’s immune system 
attacks and destroys healthy cells and tissues, as is the case 
in type 1 diabetes mellitus, celiac disease, inflammatory 
bowel diseases, and allergic asthma. Most often, the immune 
response is initiated by unknown factors. Alteration of the 
gut microbiota as a result of modern lifestyles is an attractive 
hypothesis to explain the rise in prevalence of celiac disease, 
type 1 diabetes mellitus, and inflammatory bowel diseases.
Celiac disease is an inflammatory disease of the small 
intestine that is triggered and maintained by the storage pro-
teins of wheat, barley, and rye. Studies have investigated the 
composition of the microbiota in patients with celiac disease. 
Fecal samples from patients with celiac disease had reduced 
the proportions of Bifidobacterium, Clostridium histolyticum, 
Clostridium lituseburense, Faecalibacterium prausnitzii, 
and increased proportions of Bacteroides/Prevotella.35 In 
addition, increased proportions of total and Gram-negative 
bacteria, with an increase in Bacteroides and Escherichia 
coli in biopsies of patients with celiac disease in the active 
as compared with inactive disease state and control individu-
als, was shown by fluorescence in situ hybridization coupled 
with flow cytometry.36
Type 1 diabetes mellitus, characterized by insulin defi-
ciency resulting from immune-mediated destruction of pan-
creatic β cells, is thought to be triggered by environmental 
factors in genetically susceptible individuals. Given that 
antibiotics prevented type 1 diabetes mellitus in biobreeding 
diabetes-prone rats and in nonobese diabetic mice, alteration 
of the microbiota has been associated with progression of 
type 1 diabetes mellitus.37,38 Moreover, evidence shows that 
bacterial communities from biobreeding diabetes-prone and 
diabetes-resistant rats differ, marked by a higher abundance 
of Lactobacillus and Bifidobacterium in diabetes-resistant 
rats.39
Inflammatory bowel diseases include ulcerative colitis 
and Crohn’s disease. Crohn’s disease is characterized by 
patchy and transmural inflammation that may affect any 
part of the gastrointestinal tract, while ulcerative colitis is a 
chronic episodic inflammatory condition that involves only 
the large bowel.40 There is evidence that species belonging to 
the normal gut microbiota are involved in the etiology and/or 
maintenance of inflammatory processes. Reduced microbial 
diversity, increased Bacteroidetes and Enterobacteriaceae, 
and decreased Firmicutes were all observed in patients 
with inflammatory bowel diseases.41 Another clinical study 
observed that Eubacterium rectale, B. fragilis, Bacteroides 
vulgatus, Ruminococcus albus, R. callidus, R. bromii, and 
F . prausnitzii were 5–10-fold more abundant in healthy 
subjects than in patients with Crohn’s disease, while Entero-
coccus spp, C. difficile, E. coli, Shigella flexneri, and Listeria 
spp were more abundant in the Crohn’s disease group.42 
Thus, inflammatory bowel diseases, celiac disease, and type 
1 diabetes mellitus are autoimmune diseases marked by an 
alteration of the gut microbiota. Autoimmune regulation may 
be linked with the disruption of the intestinal ecosystem.
Allergic disease
The etiology of allergic diseases is ambiguous. They may 
be initiated and maintained by environmental factors 
associated with a change in gut microbiota. Correlations 
between allergic disease and altered fecal microbiota, 
antibiotic use, and dietary changes have been made.43–45 
Studies of the microbiota in allergic patients have shown 
decreased intestinal Bifidobacteria counts, an increased 
prevalence of B. fragilis, and higher counts of Staphylococ-
cus aureus and E. coli.46–48 A study reported higher levels 
of Bifidobacterium adolescentis and Lactobacilli Group I 
(Lactobacillus rhamnosus, L. paracasei, L. casei) in fecal 
samples of nonallergic compared with allergic children.43 
Hence, it is clear that differing gut microbial communities 
have been observed in allergic patients. Further clinical 
studies are required on several age-matched groups of 
allergic versus control individuals classified with short 
age intervals.
irritable bowel syndrome
Irritable bowel syndrome is characterized by abdominal pain, 
bloating, and changes in bowel habit, in the absence of any 
overt mucosal abnormality. Observations have directed atten-
tion towards the gut microbiota, identifying a   postinfectious 
variant of the syndrome, ie, evidence that antibiotics induced 
a reduction in the microbiota which may be a risk factor, and 
the proposal that some patients may have bacterial over-
growth in the small bowel.49 Studies have demonstrated that 
patients with irritable bowel syndrome have fewer intestinal 
Bifidobacteria, Collinsella aerofaciens, Coprococcus eutac-
tus, and Clostridium cocleatum, and an increase in Veillonella 
and Enterobacteriaeae.50–52 Thus, irritable bowel syndrome 
is associated with abnormal intestinal communities, but their 
significance in the pathogenesis of irritable bowel syndrome 
remains unclear.
Metabolic disease
There are genetic and environmental factors that influ-
ence obesity, with the impact of the gut microbiota being Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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well documented. Research on the microbiota of obese 
mice establishes the link between obesity, weight gain, 
and intestinal dysbiosis. Findings indicate that a high-fat 
diet modulates the microbiota independently of obesity.53 
Mice genetically predisposed to develop obesity (ob/ob) 
harbor more Firmicutes and fewer Bacteroidetes.54 Studies 
in human twins concordant for obesity have demonstrated 
that the fractional representation of Bacteroidetes is directly 
correlated with leanness.55 Moreover, microbiota transplan-
tation from normal chow-fed ob/ob and Western diet-fed 
wild-type to germ-free wild-type mice caused an adiposity 
increase greater than that caused by transplantation from 
wild-type donors fed standard chow.56,57 This demonstrates 
a causal effect of intestinal bacteria on development of obe-
sity.   Aberrant development of the microbiota might precede 
obesity, because the childhood representation of Bifido-
bacteria and S. aureus has been suggested to predict the 
development of adulthood obesity in an inverse and direct 
manner.58 In light of these findings, a study was initiated 
which demonstrated that total short-chain fatty acids were 
higher in an obese group and individual short-chain fatty 
acid proportions shifted towards propionate in overweight 
subjects.59 It is assumed that gut dysbiosis may contribute 
to the development of obesity.
Type 2 diabetes is characterized by defects in insulin 
secretion and action. Research has characterized the fecal 
microbiota composition of adults with type 2 diabetes and 
showed reduced proportions of Firmicutes and Clostridia.60 
The ratios of Bacteroidetes to Firmicutes, as well as Bacte-
roides/Prevotella to Clostridium coccoides and E. rectale 
groups correlated positively with plasma glucose concentra-
tion. Similarly, class β-Proteobacteria was highly enriched 
in diabetic individuals and positively correlated with plasma 
glucose. Other authors have demonstrated that Prevotella was 
associated with healthy groups, while Bacteroides and Para-
bacteroides were prevalent in diabetic patients, who also had 
fewer counts of fecal B. vulgatus and   Bifidobacteria.61 The 
evidence demonstrates that metabolic diseases are associated 
with a shift in the balance of the microbiota. Confirmation of 
gut dysbiosis in type 2 diabetes patients requires additional 
clinical trials.
Alcoholic liver disease
Alcoholic liver disease, arising from excessive ingestion of 
alcohol, is the primary cause of liver failure in the Western 
world. It has been demonstrated in one study that daily 
alcohol consumption affects composition of the colonic 
microbiota.62 The authors pointed to a specific fingerprint 
of dysbiotic microbiota which could potentially identify 
susceptible heavy drinkers at high risk for alcoholic liver 
disease. Further examination is required to support fully the 
link between gut dysbiosis and alcoholic liver disease.
Bacterial infection
It is well established that a disruption in the commensal 
microbiota increases susceptibility to enteric infections. 
Antibiotic-treated mice are particularly useful for studying 
colitis induced by Salmonella spp, Shigella spp, and E. coli 
infections. In addition, in murine Citrobacter rodentium 
infections, pathogen colonization is associated with a reduced 
total density and a relative increase in γ-Proteobacteria.63 
Furthermore, elderly patients with C. difficile-associated 
diarrhea demonstrate reduced numbers of Bacteroides, 
Prevotella, and Bifidobacteria, and a greater diversity of 
facultative species, ie, Lactobacilli and Clostridia.64 The 
evidence suggests an association between disruption of the 
gut microbiota and bacterial infections, further accentuating 
the dysbiosis.
Colorectal cancer
Colorectal cancer is a disease of the Western world, with 
the most common type being adenocarcinomas which 
develop from glandular cells lining the wall of the bowel.65 
Genetic and induced models of intestinal neoplasia have 
shown that, under germ-free conditions, colitis and tumor 
formation are reduced compared with monoassociated and 
conventional animals.66–68 In addition, in vivo colonization 
of enterotoxigenic B. fragilis a human colonic commensal 
bacteria, has been linked to the development of colorectal 
cancer.69 Furthermore, colorectal cancer patients dem-
onstrate decreased levels of E. rectale and F . prausnitzii 
compared with healthy volunteers, and increased popula-
tions of E. faecalis.70 Recently, a clinical trial showed that 
patients with colorectal cancer had significant elevation of 
the Bacteroides-Prevotella population.71 Therefore, studies 
that have examined the gut microbiota in colorectal can-
cer have reported an association between microbiota and 
pathogenesis of colorectal cancer. The abnormal profile of 
bacterial communities, activities, and metabolites in human 
disease is summarized in Table 3.
The ugly
Altered composition of the human gastrointestinal ecosystem 
can lead to physiological changes in the intestinal environ-
ment, disrupting the functions of the microbiota and having 
serious consequences for human health.Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Altered gut microbiota may trigger 
serious immune deregulation
The hygiene hypothesis predicts that increased hygiene, use 
of antibiotics, and sterile food preparation result in isolation 
of the immune system from positive microbial exposure, 
favoring susceptibility to immune-mediated disorders.72 
Epidemiological studies have linked a decreasing burden 
of infection with a rising incidence of immunological 
disorders.73,74 The presence of environmental viral agents 
are also associated with the incidence of spontaneous type 
1 diabetes.75 Furthermore, the microbiota of nonobese dia-
betic mice deficient for the myeloid differentiation primary 
response gene 88 (MyD88) signaling molecule protects mice 
against developing diabetes.76 Inactivation of MyD88 leads to 
gut dysbiosis, further inhibiting the   autoimmunity occurring 
in MyD88−/− germ-free nonobese diabetic mice. These find-
ings support a causal inverse relationship between microbial 
exposure and immunological disorders.
There are several underlying mechanisms of the hygiene 
hypothesis, ie: lack of microbial burden in childhood, predis-
posing the host to allergic disorders due to a T helper type 1/ 
type 2 deviation; defective maturation of regulatory T cells 
as a consequence of modern lifestyles; antigenic competition 
from infectious agents inhibiting responses to weak antigens; 
protection from allergic diseases through mechanisms inde-
pendent of their constitutive antigens, leading to stimulation 
of nonantigen-specific receptors; and development of an 
aggressive immune response caused by genetic hyperimmu-
noreactivity triggered by dysbiosis.72 Therefore, the disrup-
tion of cross-talk between the   commensal microbiota and the 
immune system, as a result of modern lifestyles, may lead 
to development of allergic, autoimmune, and autoimmune-
associated diseases (Figure 2A).
Specific gut dysbiosis can engender 
metabolic endotoxemia
Obesity and type 2 diabetes are associated with chronic low-
grade inflammation and endotoxemia. Lipopolysaccharide 
administration and a high-fat diet lead to an increase in adipose 
tissue, impaired glucose tolerance, and insulin resistance, 
while dietary modulation reverses this phenotype.77,78 Chronic 
Table 3 imbalances of human gastrointestinal bacterial communities in human disease
imbalance of human gastrointestinal bacterial communities 
Specific overabundance 
Specific shortage 
Health status
Increase in Human disease Decrease in
Gram negative, Bacteroides-Prevotella,  
Escherichia coli
Celiac disease Gram-positive Bifidobacteria, Clostridium histolyticum   
and C. liteseburense, Faecalibacterium prausnitzii
Enterobacteriaceae, Bacteroidetes, Enterococci,  
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Figure 2 Proposed mechanisms whereby an altered microbial balance in the gut 
can lead to A) an increase in immune mediated disorders and B) chronic low-grade 
inflammation.
Abbreviations:  Th,  T  helper  type;  CD14,  cluster  of  differentiation  14;  LPS, 
lipopolysaccharide; TLR4, toll-like receptor 4.
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inflammation, elicited by endotoxemia, may cause activation 
of the immune system. The importance of gut-derived endo-
toxins in alcoholic liver disease has also been supported.79 
Circulating endotoxin levels were increased in mice and rats 
following chronic alcohol ingestion, while antibiotic treatment 
provided protection from alcoholic liver disease. In addition, 
plasma endotoxins were augmented in patients with alcoholic 
liver disease. The evidence also suggests that endotoxins 
contribute to the pathogenesis of nonalcoholic fatty liver 
disease, considered to be a hepatic manifestation of metabolic 
syndrome and obesity. Indeed, plasma endotoxins are higher in 
patients with nonalcoholic fatty liver disease and are associated 
with intestinal overgrowth and induction of hepatic toll-like 
  receptor 4.80,81 Gut permeability, which influences the systemic 
distribution of endotoxins, may further induce metabolic 
endotoxemia. Mice fed a high-fat diet demonstrate increased 
gut permeability and metabolic endotoxemia, associated with 
disruption of tight junction proteins.82 Furthermore, an increase 
in Bifidobacteria induced by nutritional supplements is cor-
related with an improved gut barrier, lower portal lipopolysac-
charide levels, and lower inflammatory tone in ob/ob mice.83 
Taken together, we suggest that gut dysbiosis, characterized 
by decreased Bifidobacteria and increased lipopolysaccharide 
release, disrupts the epithelial barrier, resulting in a leaky 
gut and leading to colonic and systemic inflammation which 
contributes to alcoholic liver disease, nonalcoholic fatty liver 
disease, obesity, and type 2 diabetes (Figure 2B). It remains 
unclear which Gram-negative bacteria are responsible for the 
increase in lipopolysaccharide.
Bacterial infection might be promoted  
by gut dysbiosis
Pathogenic bacteria can invade the gastrointestinal tract 
and infect the body, producing sepsis, shock, multisystem 
organ failure, and death of the host. The mechanisms by 
which pathogens overcome obstacles to achieve success-
ful infection are uncertain. Pathogenic infections might 
be facilitated by disruption of the intestinal ecosystem by 
environmental factors. A mechanism based on the trigger-
ing of the host’s immune defenses was elucidated using 
models of C. rodentium (mimicking diarrheal pathogen-
associated inflammation), Campylobacter jejuni infec-
tion, and chemically and genetically induced models of 
intestinal inflammation are used for altered microbiota 
investigations.63 An overgrowth of Enterobacteriaceae 
was observed in all models, indicating that inflammation-
induced microbiota changes support colonization by aero-
tolerant bacteria. The inflammatory response, triggered by 
the invading pathogen, may function to enhance its colo-
nization, further   facilitating its virulence. Thus, alteration 
of the gut microbiota, initiated by host and environmental 
factors, may participate in the initiation of diseases caused 
by infectious agent (Figure 3A).
Abnormal bacterial metabolite levels  
may trigger cancer
Many etiological bacterial mechanisms have been hypoth-
esized to promote carcinogenesis. Amongst those, hydrogen 
sulfide, a product of bacterial sulfate reduction, appears to be 
linked to the incidence of chronic disorders, such as ulcerative 
colitis and colorectal cancer. Because DNA strand breaks are 
associated with mutation and promotion of carcinogenesis, 
bacterial hydrogen sulfide may be responsible for the induc-
tion of mutations in the development of sporadic colorectal 
cancer.84 Reactive oxygen intermediates also cause DNA 
damage, and their numbers are higher in chronic inflamma-
tion and colorectal cancer, as observed in the fecal matrix.85 
In addition, hydrophobic bile acids have been shown to 
promote colorectal carcinogenesis by inducing micronuclei 
formation, mitotic perturbations, and decreases in spindle 
checkpoint proteins.86 Intestinal bacteria may also function 
as promoters of carcinogenesis by increasing the progression 
of chemically induced aberrant crypt foci.87,88 Therefore, 
despite limited studies on the occurrence of gut dysbiosis 
and tumorigenesis, we bring to a close the mechanisms that 
support the implication of detrimental intestinal bacteria in 
promoting carcinogenesis (Figure 3B).
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Figure 3 Proposed mechanism whereby an altered microbial balance in the gut can 
A) be driven by foreign pathogenic invasion and further increase the likelihood of 
future infections, and B) lead to the promotion of carcinogenesis.
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Gut microbiota alters energy and lipid 
metabolism
Gordon et al investigated the influence of microbiota on 
fat and lipid metabolism, demonstrating that reared mice 
have more body and gonadal fat than germ-free mice, 
despite reduced chow consumption. The increase in fat was 
accompanied with increased fasting glucose and insulin 
levels and an insulin-resistant state.89 Transplantation of the 
microbiota from ob/ob mice to germ-free mice resulted in 
a greater increase in body fat than from lean donors.56 Two 
mechanisms are suggested. First, colonization of the gut 
may suppress expression of fasting-induced adipose factor, 
increasing the activity of lipoprotein lipase, leading to an 
increased uptake of fatty acids and triglyceride storage. The 
second mechanism is based on the processing of dietary poly-
saccharides by bacteria that may increase hepatic lipogenesis 
through expression of sterol response element binding protein 
1 and carbohydrate response element binding protein. Other 
authors suggest that the complex formed by short-chain 
fatty acids and G protein-coupled receptor 41 may increase 
circulating levels of peptide YY, which may further increase 
energy extraction from the diet.90 It was also demonstrated 
that in the absence of gut microbiota, AMP-activated protein 
kinase activity is constitutively higher in muscle, leading 
to higher phosphorylation of its specific target, acetyl CoA 
carboxylase, promoting mitochondrial fatty acid oxidation.91 
Finally, the microbiota may affect insulin resistance and 
steatosis by regulating choline metabolism.92 Thus, altera-
tion of the gut microbiota causes defective energy and lipid 
metabolism leading to the development of metabolic disease 
(Figure 4).
Alter the gut microbiota to favor 
human health
The relationship between health and the gastrointestinal 
system is established. Due to the inherent plasticity of 
microbiota, one can consider exploiting it to develop 
biotherapeutics.
Probiotics
Probiotics are “live microorganisms, which, when admin-
istered in adequate amounts, confer a health benefit on 
the host”.93 Probiotics have been shown to have effects on 
irritable bowel diseases, metabolic syndromes, enterocoli-
tis, immunomodulation, pathogen defense, and urogenital 
infections.94–96 Mechanisms of probiotics include remodeling 
of microbial communities and suppression of pathogens, 
suppression of proinflammatory factors, effects on epithelial 
cell differentiation, and proliferation and promotion of the 
intestinal barrier.97
Microencapsulation and other methods 
for targeted delivery
Microencapsulation, which provides living cells with a 
physical protection barrier, is primarily used to improve 
probiotic activity during gastrointestinal transit, while allow-
ing the diffusion of metabolites and substrates into and out 
of the capsule. Secondly, it offers a bacterial delivery sys-
tem targeted to a specific part of the gastrointestinal tract. 
Thirdly, microencapsulation ensures immunomodulation by 
preventing interaction between the host immune system and 
entrapped probiotic bacterial cells.98,99 In addition, there are 
other excellent formulations available for delivery of probi-
otic cells to achieve optimal clinical benefits.
Prebiotics
Prebiotics are “nondigestible food ingredients that benefi-
cially affect the host by selectively stimulating the growth 
and/or the activity of one or a limited number of  bacteria in the 
colon, and thus improves host health”.100 A prebiotic should 
not be hydrolyzed by human intestinal enzymes, but selec-
tively fermented by bacteria, benefiting the host. Effects of 
prebiotic administration include reduced triglyceride levels, 
improved postprandial glucose levels, and reduced intestinal 
permeability and inflammation.100–102 In addition to prebiotics, 
known foods and drugs are also being developed to enhance 
the growth of health-promoting bacterial cell populations 
in the gastrointestinal tract, with the aim of preventing or 
treating a number of diseases.
Symbiotic association of probiotics  
and prebiotics
It has been hypothesized that in combining probiotics and 
prebiotics, one would not only achieve the combined effects 
of the two components, but also a synergistic effect. This is 
the principle on which symbiotics are based.103
Antibiotics combined with probiotics
The evidence suggests that probiotic bacteria suppress gas-
trointestinal pathogens and potentiate antibiotic efficacy by 
production of antibacterial factors, including bacteriocins.97 
With the use of antibiotic drugs, bacterial overgrowth can 
be controlled, and translocation in specific conditions of 
increased risk can be prevented.83 In brief, strong evidence 
is available that probiotics, prebiotics, and antibiotics can 
successfully exploit the natural microbial composition of Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the gut to treat and/or prevent diseases for improving human 
health and well being.
Future directions
Advances in exploring and modeling the microbiota are 
generating a wealth of knowledge about human health and 
disease, and contributing to the development of new biothera-
peutics. Significant advances have been made in the   selection 
and characterization of specific probiotic cultures and/or 
prebiotics and subsequent substantiation of health claims 
relating to their consumption. However, there is still much 
skepticism in the medical community with respect to the 
effects demonstrated. Firstly, the disease model used affects 
the results significantly. Secondly, there is a lack of large, 
controlled, randomized human trials supporting the beneficial 
claims. Thirdly, the harsh conditions of the gastrointestinal 
tract can impede the delivery of probiotic bacterial cells. 
One significant advantage of using prebiotics as opposed to 
probiotics is that they overcome the viability issue. Prebiot-
ics are, by definition, not hydrolyzed by enzymes during 
  gastrointestinal transit and, therefore end up being available 
to stimulate selective growth of gut microbiota. Nevertheless, 
it is hardly possible to demonstrate the selectivity criterion of 
prebiotics. On the contrary, microencapsulation of probiotic 
bacteria is a delivery method that overcomes the viability 
issue and is also selective.
Therefore, it is easy to envisage that microencapsulated 
probiotics may soon be available on the market, and research 
in the long term may focus on developing formulations 
combining microencapsulated probiotics, prebiotics and/or 
antibiotics. The main challenge is developing suitable models 
to characterize and understand the microbiota, and develop-
ing effective treatment formulations, such as targeted delivery 
of probiotics within the gastrointestinal tract.
Towards new models of human gut 
microbiota
In vitro models of the human microbiota are essential to 
screen, characterize, develop, and perform mechanistic 
studies under controlled parameters. To test the therapies 
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being developed effectively, special attention has to be 
directed to the development and optimization of in vitro 
models of the microbiota, given that these are rare.   Models 
to mimic the whole gastrointestinal tract and specific 
compartments are essential. The challenge is to create a 
fermentation system featuring microbial diversity similar 
to that in the human gastrointestinal tract. Due to sam-
pling complications, the microbiota of a fecal inoculum is 
assumed to be representative of the intestinal microbiota.104 
The computer-controlled dynamic human gastrointestinal 
model consists of a succession of five vessels: the stom-
ach, the small intestine, and the ascending, transverse, and 
descending colon (Figures 5A and 5B).105,106 Temperature, 
pH, and anaerobic parameters are all controlled using 
  Labview® software. The system is equipped with portholes 
for the addition of medium, the removal of spent culture, and 
the administration of   therapeutics. Attention is also needed 
to simulate the bacterial microhabitat of the intestines, 
because the metabolism and functioning of the mucosal-
associated microbiota differ from those free-living in the 
lumen.106 Efforts should be made to understand the effect of 
gastrointestinal tract adhesion of bacterial cells on bacterial 
metabolism by designing a model to investigate adhesion 
of probiotics for gut   microbiota modulation.
Microencapsulation to boost efficacy  
of probiotic treatment
There are many methods for microencapsulation of bacte-
rial cells available, and these can be effectively used in 
boosting probiotic oral delivery and clinical efficacy. Our 
research interest is mainly focused on the customization 
of a myriad of microencapsulated probiotic formulations 
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Figure 5 Computer-controlled dynamic human gastrointestinal (Gi)  model used for studies on the human gut microbiota. A) Schematic representation, B) photograph. 
vessels in series representing stomach, small intestine, ascending colon, transverse colon, and descending colon. All vessels can be continuously magnetically stirred; 
temperature can be controlled by the flow of hot water in the double jacketed vessel. Food can be given at a time interval and samples can be collected from any GI part at 
any time (eg, spent removal of the spent culture at defined intervals). This also allows for the administration of biotherapeutics, control of pH, enzyme, anerobic atmosphere 
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using polyelectrolyte complexation, a widely used technique 
based on the interaction of oppositely charged polymers that 
form a physical membrane around the probiotic.99,105–111 The 
physicochemical properties of the capsules are engineered 
to guarantee survival of the bacteria, appropriate diffusion 
of metabolites and substrates, and targeted delivery. In 
gastrointestinal tract simulators, the enzymatic activity, 
stability, and viability of microencapsulated probiotics 
have been demonstrated.105–109 Results confirm the potential 
of orally delivered microencapsulated bacteria to manage 
hypercholesterolemia, hypertriglyceridemia, and colon 
cancer.108,111 For microencapsulated probiotics to be market-
able, research must be directed at developing structural and 
functional models of the microbiota to test the therapeutic 
formulations. Finally, in vivo models should evaluate the 
efficacy of microencapsulated probiotic formulations while 
characterizing preclinical cellular and tissue responses. The 
potential of microencapsulated Lactobacillus fermentum 
to lower cholesterol and triglycerides in Bio F(1)B ham-
sters fed a hypercholesterolemic diet was investigated.108 
Treatment with the bacterial formulation reduced total 
cholesterol, low-density lipoprotein cholesterol, and triglyc-
erides, and also reduced the progression of atherosclerotic 
lesions. The antitumorigenic properties of microencapsu-
lated probiotics in multiple intestinal neoplasia were also 
investigated in mice carrying a germline APC mutation.111 
Oral administration of microencapsulated Lactobacillus 
acidophilus resulted in suppression of colon tumor inci-
dence, multiplicity, and size. Preclinical trials confirm the 
potential of orally delivered microencapsulated probiotics 
for managing hypercholesterolemia, hypertriglyceridemia, 
and colon cancer.
Conclusion
This is an extensive and timely review of the gut microbiota 
and its role in human health and disease. First described are 
the key players among the microbiota, how they develop into 
a network in the gastrointestinal tract, their roles in various 
gastrointestinal and other diseases, methods to study human 
gut microbiota, and associated health benefits and limita-
tions. Interest in the microbiota arose after the realization 
that an altered balance in the gut could lead to disease. By 
using probiotics, prebiotics, and antibiotics, one can tune 
the composition of the gut to improve the health of the host. 
Optimization of methods to modulate and characterize the 
microbiota and probiotics still remains to be done. The 
microbiota itself can allow for the analysis of health, and 
biomarkers of a given microbiota can be indicative of disease. 
Although preliminary, two animal models have shown that 
microbial metabolism is correlated with specific patterns of 
metabolites excreted in urine.112 This could potentially be a 
significant breakthrough in the new realm of personalized 
medicine.
Gut microbiota is an area of research with potential for 
pure scientific exploration with significant biotherapeutic 
applications. It remains largely unexplored. This is due to the 
complexity of the microbiota and the difficulties in collection 
and analysis of data. In addition, lack of understanding of 
the role of bacterial cells in human health and lack of well 
defined clinical trials on known beneficial probiotics, other 
bacterial cells, and associated systems, such as delivery 
systems, are seriously hampering this very important area 
of biological therapy. Development of cutting-edge tech-
nologies for understanding human gut microbiota, their 
manipulations, and screening and development of cutting 
edge formulations for probiotic delivery, such as micro-
encapsulation, are strongly needed, along with accurate 
in vitro models.
Highlights
The  human  gut  microbiota  is  an  asset  for  human 
homeostasis.
•	 The human gut microbiota, which resides within the 
gastrointestinal tract system, is composed of trillions 
of microorganisms with tremendous diversity and 
complexity
•	 The gut microbiota should be considered as a vital organ, 
carrying essential metabolic, protective, and structural/
histological functions in maintaining body homeostasis, 
human health and other manifestations
•	 An altered composition of the intestinal ecosystem, a state 
called gut dysbiosis, can lead to physiological changes 
in the intestinal environment, disrupting the functions 
of the gut microbiota, autoimmune, allergic, metabolic 
and alcoholic liver diseases, irritable bowel syndrome, 
colorectal cancer, and bacterial infections have all been 
linked to gut dysbiosis
•	 Bacterial imbalances can be responsible for immunologi-
cal deregulation, breakdown of colonization resistance, 
induction of systemic endotoxemia, production of car-
cinogenic compounds and alteration of energy and lipid 
metabolism
•	 Due to the inherent plasticity of the gut microbiota, 
therapeutics such as probiotics, prebiotics, and antibiotics 
are used to modulate the human intestinal ecosystem to 
obtain better human healthBiologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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•	 Major efforts should be directed towards development of 
in vitro and in vivo models to understand the human gut 
microbiota and explore development of biotherapeutic 
possibilities and methods, such as microencapsulation, for 
suitable delivery of beneficial bacterial cells to the gas-
trointestinal tract and other systems for human health.
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